Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results ...

Announced increased focus on type 1 diabetes and in vivo CAR T programsRegulatory interactions increase confidence in moving forward with GMP ...

Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders ...

ITAT Pune ruled that the late filing of the Form 10B audit report is not fatal to the charitable trust exemption if filed before assessment completion. The court reversed the disallowance of ...

Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to ...

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...

Most students who applied for South Carolina’s private K-12 tuition aid program this year were either already attending ...

Please note that the limited information that follows in this press release is not adequate to make an informed investment ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to pr ...

Neuropace, Inc. ( ($NPCE) ) has released its Q3 earnings. Here is a breakdown of the information Neuropace, Inc. presented to its investors.

A DENTAL surgery can finally expand its practice after the Government stepped in to end a long planning battle.